Search alternatives:
significantly marked » significantly larger (Expand Search), significantly linked (Expand Search), significantly improved (Expand Search)
marked decrease » marked increase (Expand Search)
i decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
significantly marked » significantly larger (Expand Search), significantly linked (Expand Search), significantly improved (Expand Search)
marked decrease » marked increase (Expand Search)
i decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
1
Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index.
Published 2025“…All groups were compared by Kruskal Wallis test with <i>post hoc</i> test after Dunn with Bonferroni adjustment showing significant decreased Ki-67 labeling index of <i>Cina1</i> compared to <i>Cina2</i> (p = 0.006) and the untreated CKD groups (p = 0.0001 and p = 0.0002, respectively). …”
-
2
-
3
-
4
-
5
-
6
-
7
-
8
Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i>
Published 2025“…(B, C) Summarized bar graph showed EVO significantly decreased calcium deposition and calcium content in CER treated P<sub>i</sub>-induced VSMCs. …”
-
9
-
10
-
11
-
12
-
13
-
14
Altered expression of genes related to Ca<sup>2+</sup> cycling or myocardial contraction.
Published 2025Subjects: -
15
-
16
-
17
-
18
Linear covariate analysis of prognostically significant metabolites. Presenting the effect sizes of metabolites that showed significant differences among prognostic groups in ICU-treated COVID-19 patients. Metabolites were included based on an F-value > 2.5 and a p-value < 0.05. Metabolites marked with a single asterisk (*) were significant in both two-way ANOVA and ASCA, whereas those marked with double asterisks (**) were significant only in two-way ANOVA....
Published 2025“…Metabolites were included based on an F-value > 2.5 and a p-value < 0.05. Metabolites marked with a single asterisk (*) were significant in both two-way ANOVA and ASCA, whereas those marked with double asterisks (**) were significant only in two-way ANOVA. …”
-
19
Metabolites with decreasing levels during the development.
Published 2025“…<p>Temporal profiles of polar metabolites and lipids with SCN levels significantly decreasing from E19 to P28. Rhythmicity was determined by eJTK; full or dashed lines depict the profiles that either did or did not pass the significance threshold (FDR-adjusted <i>P</i> < 0.05), respectively.…”
-
20
Evogliptin attenuates the pyroptotic cell death of VSMCs during CER treatment by decreasing the pyroptotic-associated genes and GSDM-D cleavage efficiency <i>in-vitro.</i>
Published 2025“…<p>(A) Bar graph showed EVO significantly decreased Lactate dehydrogenase (LDH) release in CER treated P<sub>i</sub>‐induced VSMCs. …”